COVID-19 Antibody Assays
SARS-CoV-2 Neutralizing Antibody ELISA Kit:
Evaluation of immune response after COVID-19 vaccination and infection.
- Quantitative, high throughput analysis for neutralizing antibodies in blood samples.
- Particularly suitable for determining the neutralizing antibody titer after COVID-19 vaccination.
- Neutralizing antibodies resulting from vaccination blocks the invasion of virus into host cells.
- The ELISA specifically quantifies the neutralizing antibody titer of those antibodies, which will:
– Block the receptor-binding domain (RBD) of the S1 subunit of virus’ Spike protein.
– Thereby preventing the S1-RBD attachment to the human host cell ACE2 receptor.
- This is achieved in a 1-step competitive ELISA based on:
– ELISA-wells precoated with S1-RBD
– Simultaneous competitive incubation of blood sample (antibodies) and peroxidase-labeled ACE-2
- It takes little manual labor to analyze hundreds of samples in one run.
- Clinically documented, 1-step RUO ELISA kit including all necessary reagents.
Order Product no. SOL-COV-2 from Solsten by E-mail: info@solsten-diag.com or Phone: +45 2577 3393.

The Solsten SARS-CoV-2 Neutralizing Antibody ELISA Kit is a useful tool for quantifying the individual, time-dependent response to vaccination with COVID-19 vaccines from Pfizer-Biontech, Moderna, Astra Zeneca and Johnson&Johnson. Reference: Finalized study per January 11, 2022 at Solsten Diagnostics.

The Solsten SARS-CoV-2 Neutralizing Antibody ELISA is a 1-step competitive assay, where neutralizing antibodies in the blood sample competes with the peroxidase-labeled human ACE-2 receptor to bind to the immobilized receptor-binding domain of the virus’ Spike protein (S1-RBD). The reduction in color signal is proportional to the antibody-derived protection (titer) against the virus.